<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1998
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 0-28782
-------
NEOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
DELAWARE 93-0979187
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
157 TECHNOLOGY DRIVE
IRVINE, CALIFORNIA 92618
(Address of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, Including Area Code: (949) 788-6700
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
--- ---
Indicate the number of shares outstanding of each of the issuer's classes of
Common stock as of the latest practicable date:
<TABLE>
<CAPTION>
Class Outstanding at May 4, 1998
--------------------------- --------------------------
<S> <C>
Common Stock, $.001 par value 5,474,307
</TABLE>
1
<PAGE> 2
NEOTHERAPEUTICS, INC.
(A Development-Stage Enterprise)
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PART I. FINANCIAL INFORMATION Page No.
--------
<S> <C> <C>
ITEM 1. FINANCIAL STATEMENTS
Statement regarding financial information............................... 3
Condensed Consolidated Balance Sheets as of March 31, 1998 and
December 31, 1997................................................... 4
Condensed Consolidated Statements of Operations for the three
months ended March 31, 1998 and 1997 and for the period from
inception (June 15, 1987) to March 31, 1998......................... 5
Condensed Consolidated Statements of Cash Flows for the three
months ended March 31, 1998 and 1997 and for the period from
inception (June 15, 1987) to March 31, 1998......................... 6
Notes to Condensed Consolidated Financial Statements.................... 8
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL
POSITION................................................................ 13
PART II. OTHER INFORMATION....................................................... 16
ITEM 2. Changes in Securities and Use of Proceeds............................... 16
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K........................................ 19
</TABLE>
2
<PAGE> 3
NEOTHERAPEUTICS, INC.
(A Development Stage Enterprise)
FORM 10-QSB
FOR THE QUARTER ENDED MARCH 31, 1998
------------------------------------
PART I
FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
STATEMENT REGARDING FINANCIAL INFORMATION
- -----------------------------------------
The financial statements included herein have been prepared by
NeoTherapeutics, Inc. (the "Company"), without audit, pursuant to the rules and
regulations of the Securities and Exchange Commission. Certain information
normally included in the financial statements prepared in accordance with
generally accepted accounting principles has been condensed or omitted pursuant
to such rules and regulations. However, the Company believes that the
disclosures are adequate to make the information presented not misleading. It is
suggested that the financial statements be read in conjunction with the
financial statements and notes thereto included in the Company's Annual Report
on Form 10-KSB for the fiscal year ended December 31, 1997 as filed with the
Securities and Exchange Commission.
3
<PAGE> 4
NEOTHERAPEUTICS, INC. AND SUBSIDIARIES
(A Development-Stage Enterprise)
CONDENSED CONSOLIDATED BALANCE SHEETS
MARCH 31, 1998 AND DECEMBER 31, 1997
<TABLE>
<CAPTION>
March 31, December 31,
ASSETS 1998 1997
------------ ------------
CURRENT ASSETS: (Unaudited)
<S> <C> <C>
Cash and cash equivalents $ 3,669,957 $ 6,063,347
Restricted cash -- 935,000
Marketable securities and short-term investments 2,192,366 2,133,375
Other receivables, principally investment interest 91,351 221,829
Prepaid expenses and refundable deposits 241,682 127,259
------------ ------------
Total current assets 6,195,356 9,480,810
------------ ------------
PROPERTY AND EQUIPMENT, at cost:
Equipment 2,040,605 1,952,262
Leasehold improvements 1,776,391 1,803,000
Accumulated depreciation and amortization (386,648) (279,913)
------------ ------------
Property and equipment, net 3,430,348 3,475,349
------------ ------------
DEFERRED CHARGES AND DEPOSITS 214,739 242,314
------------ ------------
TOTAL ASSETS $ 9,840,443 $ 13,198,473
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Line of credit $ -- $ 850,000
Accounts payable and accrued expenses 724,032 975,339
Accrued payroll and related taxes 79,677 --
Notes payable to related party 558,304 558,304
Current portion of long-term debt 89,085 94,886
------------ ------------
Total current liabilities 1,451,098 2,478,529
LONG-TERM DEBT, net
of current portion 151,584 176,549
DEFERRED RENT 11,576 --
------------ ------------
Total liabilities 1,614,258 2,655,078
------------ ------------
STOCKHOLDERS' EQUITY:
Common stock, no par value, 25,000,000 shares
authorized:
Issued and outstanding, 5,474,307 and 5,465,807
shares at March 31, 1998 and December 31, 1997,
respectively 23,378,034 23,188,363
Unrealized gains on available-for-sale securities 21,666 20,256
Deficit accumulated during the development stage (15,173,515) (12,665,224)
------------ ------------
Total stockholders' equity 8,226,185 10,543,395
------------ ------------
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY $ 9,840,443 $ 13,198,473
============ ============
</TABLE>
The accompanying notes are an integral part of these condensed consolidated
balance sheets.
4
<PAGE> 5
NEOTHERAPEUTICS, INC. AND SUBSIDIARIES
(A Development-Stage Enterprise)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 1998
AND 1997 AND THE PERIOD FROM
INCEPTION (JUNE 15, 1987) TO MARCH 31, 1998
<TABLE>
<CAPTION>
Three Months Three Months Inception
Ended Ended Through
March 31, March 31, March 31,
1998 1997 1998
-------------- -------------- -------------
(Unaudited) (Unaudited) (Unaudited)
<S> <C> <C> <C>
REVENUES, from grants $ - $ - $ 497,128
-------------- -------------- -------------
OPERATING EXPENSES:
Research and development 1,787,962 548,815 9,263,029
General and administrative 740,289 498,964 6,510,671
-------------- -------------- -------------
Total operating expenses 2,528,251 1,047,779 15,773,700
-------------- -------------- -------------
LOSS FROM OPERATIONS (2,528,251) (1,047,779) (15,276,572)
-------------- ------------- -------------
OTHER INCOME (EXPENSE):
Interest income, net 28,771 228,804 514,168
Other income (expense) (8,811) - 37,889
-------------- -------------- -------------
Total other income 19,960 228,804 552,057
-------------- -------------- -------------
NET LOSS $ (2,508,291) $ (818,975) $ (14,724,515)
============== ============= =============
BASIC AND DILUTED LOSS
PER SHARE $ (0.46) $ (0.15)
============== =============
Basic and Diluted Weighted Average
Shares Outstanding 5,467,206 5,361,807
============== ==============
</TABLE>
The accompanying notes are an integral part of these condensed
consolidated statements.
5
<PAGE> 6
NEOTHERAPEUTICS, INC. AND SUBSIDIARIES
(A Development-Stage Enterprise)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 1998 AND 1997
AND THE PERIOD FROM INCEPTION (JUNE 15, 1987) TO MARCH 31, 1998
<TABLE>
<CAPTION>
Period from
Three Months Three Months Inception
Ended Ended Through
March 31, March 31, March 31,
1998 1997 1998
------------ ------------ ------------
(Unaudited) (Unaudited) (Unaudited)
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) $ (2,508,291) $ (818,975) $(14,724,515)
Adjustments to reconcile net loss to net
cash used in operating activities
Depreciation and amortization 106,735 11,472 512,137
Compensation expense arising from
stock options issued for services 134,442 60,000 403,391
Amortization of deferred compensation -- -- 93,749
Increase in deferred rent 11,576 -- 11,577
Compensation expense for extension of
Debt Conversion Agreements, net -- -- 503,147
Gain on sale of assets -- -- (5,299)
Decrease (increase) in other receivables 130,478 (86,116) (91,105)
(Increase) in prepaid expenses,
deferred charges and refundable deposits (86,848) (24,874) (406,418)
(Decrease) increase in accounts
payable and accrued expenses (251,308) 21,780 884,131
Increase (decrease) in accrued payroll
and related taxes 79,677 (295,648) 718,371
Decrease (increase) in employee
expense reimbursement and accrued
interest to related parties -- (205,113) 300,404
------------ ------------ ------------
Net cash used in operating activities (2,383,539) (1,337,474) (11,800,430)
------------ ------------ ------------
</TABLE>
6
<PAGE> 7
NEOTHERAPEUTICS, INC. AND SUBSIDIARIES
(A Development-Stage Enterprise)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
<TABLE>
<CAPTION>
Period from
Three Months Three Months Inception
Ended Ended Through
March 31, March 31, March 31,
1998 1997 1998
------------ ------------ ------------
(Unaudited) (Unaudited) (Unaudited)
<S> <C> <C> <C>
CASH FLOWS FROM INVESTING
ACTIVITIES:
Purchases of property and
equipment (61,734) (1,661,270) (3,897,299)
Purchases of marketable
securities and short-term
investments, net (58,991) (3,776,146) (2,192,366)
Unrealized gain on
available-for-sale
securities 1,410 -- 21,666
Payment of organization costs -- -- (66,093)
Proceeds from sale of equipment -- -- 29,665
Issuance of notes receivable -- -- 100,000
------------ ------------ ------------
Net cash used in investing activities (119,315) (5,437,416) (6,004,427)
------------ ------------ ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from common stock issuance
including Revenue Participation
Units converted to common stock 55,230 -- 20,275,634
Repayment of bank line of credit (850,000) -- --
Decrease in restricted cash 935,000 -- --
(Repayment) issuance of installment
note payable (30,766) -- 240,668
Proceeds from notes payable to
related parties, net -- -- 757,900
Cash at acquisition -- -- 200,612
------------ ------------ ------------
Net cash provided by financing
activities 109,464 -- 21,474,814
------------ ------------ ------------
Net increase (decrease) in cash (2,393,390) (6,774,890) 3,669,957
Cash, beginning of period 6,063,347 9,995,062 --
------------ ------------ ------------
Cash, end of period $ 3,669,957 $ 3,220,172 $ 3,669,957
============ ============ ============
</TABLE>
The accompanying notes are an integral part of these condensed
consolidated statements.
7
<PAGE> 8
NEOTHERAPEUTICS, INC. AND SUBSIDIARIES
--------------------------------------
(A Development-Stage Enterprise)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
----------------------------------------------------
MARCH 31, 1998
--------------
(Unaudited)
-----------
1. Summary of Significant Accounting Policies
a. Organization and Nature of Business
In the opinion of the Company's management, the accompanying
unaudited condensed consolidated financial statements include all adjustments
(which consist only of normal recurring adjustments) necessary for a fair
presentation of its consolidated financial position at March 31, 1998 and
consolidated results of operations and cash flows for the periods presented.
Although the Company believes that the disclosures in these financial statements
are adequate to make the information presented not misleading, certain
information and disclosures normally included in financial statements prepared
in accordance with generally accepted accounting principles have been condensed
or omitted and should be read in conjunction with the Company's audited
financial statements included in the Company's Annual Report on Form 10-KSB for
the fiscal year ended December 31, 1997 as filed with the Securities and
Exchange Commission. Results of operations for the three months ended March 31,
1998 are not necessarily indicative of results to be expected for the full year.
NeoTherapeutics, Inc. (the "Company") was incorporated in Colorado
as Americus Funding Corporation ("AFC") in December 1987. In August 1996, AFC
changed its name to "NeoTherapeutics, Inc." and in June 1997, the Company was
reincorporated in the state of Delaware. The Company has two wholly-owned
subsidiaries, Advanced ImmunoTherapeutics, Inc. ("AIT"), incorporated in
California in June 1987, and NeoTherapeutics, GmbH, incorporated in Switzerland
in April 1997. All references to the "Company" hereinafter refer to
NeoTherapeutics and its subsidiaries as a consolidated entity.
The Company is a development-stage biopharmaceutical enterprise
engaged in the discovery and development of novel therapeutic drugs intended to
treat neurodegenerative diseases and conditions such as memory deficits
associated with Alzheimer's disease and aging, stroke, spinal cord injuries and
Parkinson's disease.
b. Principles of Consolidation
The consolidated financial statements include the accounts of the
Company and its subsidiaries. All significant intercompany accounts and
transactions have been eliminated.
c. Research and Development
All costs related to research and development activities are
treated as expenses in the period incurred.
8
<PAGE> 9
NEOTHERAPEUTICS, INC. AND SUBSIDIARIES
(A Development-Stage Enterprise)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
d. Marketable Securities and Short Term Investments
The Company accounts for investments in marketable securities
under Statement of Financial Accounting Standards ("SFAS") No. 115, "Accounting
for Certain Investments in Debt and Equity Securities." The statement requires
investments in debt and equity securities to be classified among three
categories as follows: held-to-maturity, trading and available-for-sale. As of
March 31, 1998, securities held by the Company were classified as
"held-to-maturity" and "available-for-sale." Securities held-to-maturity are
stated at cost, adjusted for amortization of premiums and accretion of
discounts, which are recognized as adjustments to interest income on investment
securities. A valuation allowance is not established to recognize temporary
market value fluctuations as the Company has the intent and ability to hold
these investments until maturity. Available-for-sale securities are carried at
fair value, with unrealized gains and losses reported as a separate component of
stockholders' equity. Quoted market prices have been used in determining the
fair value of these investments. Short-term investments consist of commercial
paper and equivalent corporate obligations, corporate bonds and U.S. Government
obligations and are stated at amortized cost with respect to held-to-maturity
investments, and at fair value with respect to investments classified as
available-for-sale securities.
e. Stock Based Compensation
The Financial Accounting Standards Board issued SFAS No. 123,
"Accounting for Stock-Based Compensation" in October 1995. SFAS 123 encourages
companies to adopt a fair value approach to valuing stock options that would
require compensation cost to be recognized based on the fair value of stock
options granted. The Company has elected as permitted by the standard, to
continue to follow its intrinsic value based method of accounting for stock
options consistent with Accounting Principles Board (APB) Opinion No. 25,
"Accounting for Stock Issued to Employees." Under the intrinsic method,
compensation cost for stock options is measured as the excess, if any, of the
quoted market price of the Company's stock at the measurement date over the
exercise price.
f. Net Loss Per Share
Net loss per share is calculated using the weighted average number
of shares outstanding for the period. Common equivalent shares are excluded from
the computation as their effect is antidilutive. In February 1997 the Financial
Accounting Standards Board issued SFAS No. 128, "Earnings Per Share," which
requires companies to present basic earnings per share and diluted earnings per
share, instead of the primary and fully diluted earnings per share (EPS) as
previously required. The new standard requires additional information
disclosures and also makes certain modifications to the EPS calculations defined
in APB No. 15. There were no differences between loss per share as previously
reported under APB No. 15 for the three month period ended March 31, 1997 and
basic and diluted loss per share for this period as reported under SFAS No. 128.
9
<PAGE> 10
NEOTHERAPEUTICS, INC. AND SUBSIDIARIES
(A Development-Stage Enterprise)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
g. New Pronouncements
Effective January 1, 1998, the Company adopted SFAS No. 130,
"Reporting Comprehensive Income." Comprehensive income is a broad concept of an
enterprise's financial performance, in that it includes all changes in equity
during a period from transactions and events from nonowner sources. For the
three months ended March 31, 1998, comprehensive income (loss) was not
materially different from net income (loss).
SFAS No. 131, "Disclosures About Segments of an Enterprise and
Related Information" is effective for financial statements for periods beginning
after December 15, 1997. The Company does not believe that adoption of this
standard will materially affect the financial statements.
h. Use of Estimates
The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
2. Debt
Line of Credit:
The Company has available through August 30, 1998, a line of credit
agreement with its bank, whereby it may borrow up to $1,600,000. Borrowings are
collateralized by cash or marketable securities acceptable to the bank, equal to
approximately 111% of the outstanding loan amount. Interest on any borrowings is
payable at the lower of the bank's prime rate or another similar index as
specified in the Agreement. At March 31, 1998, the Company had no borrowings
under this line of credit.
Long-Term Debt:
The Company has financed the premium for a three year insurance policy.
The loan is payable through August 2000 in monthly installments of $9,475,
including 8.25% interest.
3. Commitments and Contingencies
Facility Leases:
During June 1997, the Company relocated to a new facility which it
occupies under a non-cancelable operating lease expiring in June 2004. The lease
contains two five year options to renew at the fair value rates in effect at the
time of renewal. Minimum monthly rents under this lease range from $38,800 to
$47,600 through its term. The total minimum commitment under the new facility
lease aggregates approximately $3.3 million through June 2004.
10
<PAGE> 11
NEOTHERAPEUTICS, INC. AND SUBSIDIARIES
(A Development-Stage Enterprise)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
Research and Fellowship Grants:
The Company periodically makes non-binding commitments to various
Universities and not-for-profit research organizations to fund scientific
research and fellowship grants that may further the Company's research programs.
As of March 31, 1998, the Company had committed to pay, through October 1998,
approximately $382,000 for such grants and fellowships. Grant expense for the
three-month periods ended March 31, 1998, and 1997 amounted to $71,000 and
$99,500, respectively.
4. Common Stock
Line of Equity Agreement:
On March 27, 1998, the Company executed an Agreement with a private
investor for a $15 million equity line. The Agreement runs for a thirty month
period commencing on the effective date of a Registration Statement that was
filed on May 11, 1998 with the Securities and Exchange Commission. The Agreement
provides for the Company, at its sole discretion, and subject to certain
restrictions, to periodically sell ("put") shares of its common stock to the
investor. Puts can be made every 15 days in amounts ranging from $250,000 to
$2,000,000, depending on the trading volume and the market price of the stock at
the time of each put, subject to aggregate minimum puts of $1 million over the
life of the Agreement. At the time of each put, the investor receives a discount
of 12% from the then current average market price, as determined under the
Agreement, and the Company is required to pay sales commissions consisting of
cash and shares of common stock to a financial advisor who acted as a finder in
this transaction. The Agreement also required the Company to issue to the
investor warrants to purchase 25,000 shares of common stock at $11.62 per share.
Common Stock Subject to Forfeiture:
In 1990 and 1993, certain founders and former key employees of the
Company entered into Agreements to convert accrued salaries and unreimbursed
expenses to an aggregate of 678,834 shares of common stock, of which 400,244
shares are owned by the Company's Chief Executive Officer and his wife, the
Secretary-Treasurer of the Company. Under the Agreements, as amended, all of the
shares issued are subject to forfeiture (and cancellation) if the Company failed
to meet certain revenue goals over a period that expired December 31, 1997. Such
revenue goals were not met. However, certain of the former employees are
disputing, among other things, whether the revenue goals were met and,
consequently, have not surrendered their stock for cancellation. The Company's
Chief Executive Officer and the Secretary-Treasurer have indicated that they are
willing to conditionally surrender their shares, subject to the ultimate
resolution of the dispute with the aforementioned former employees. Until the
ultimate resolution of this matter and the surrender and cancellation of these
shares, the Company is accounting for all of such common stock, which it has
deemed forfeited, as issued and outstanding.
11
<PAGE> 12
NEOTHERAPEUTICS, INC. AND SUBSIDIARIES
(A Development-Stage Enterprise)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
5. Stock Options:
Stock option activities for the three month period ended March 31, 1998
were as follows:
<TABLE>
<CAPTION>
Option Price
Shares per Share
------ ---------
<S> <C> <C>
Outstanding at December 31, 1997 658,173 $0.025-$12.88
Granted 123,300 8.38-8.88
Exercised (4,500) 3.75-4.50
Expired -- --
-------- -------------
Outstanding at March 31, 1998 776,973 $0.025-$12.88
======== =============
</TABLE>
During the three month periods ended March 31, 1998 and 1997, the
Company recognized compensation expense for vested consultant options pursuant
to SFAS 123 of $134,442 and $60,000, respectfully. Options granted to
consultants consist of options that vest both immediately and upon the
occurrence of certain events as specified in the related agreements.
12
<PAGE> 13
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
FINANCIAL POSITION
PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
- -----------------------------------------------------
This Quarterly Report on Form 10-QSB contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. The Company's actual results may differ
materially from the results projected in the forward-looking statements. Factors
that might cause such a difference include, but are not limited to, those
discussed below under "Factors Affecting Future Operating Results."
RESULTS OF OPERATIONS
- ---------------------
Overview:
From the inception of the Company in 1987 through March 31, 1998, the
Company incurred a cumulative net loss of approximately $14.7 million. The
Company expects its operating expenses to increase over the next several years
as it continues to expand its research and development and commercialization
activities and operations. The Company expects to incur significant additional
operating losses for at least the next several years unless such operating
losses are offset, if at all, by licensing revenues under strategic alliances
with larger pharmaceutical companies which the Company is currently seeking.
Three Months Ended March 31, 1998 Compared to Three Months Ended March
31, 1997:
There were no revenues during the three months ended March 31, 1998 or
the three months ended March 31, 1997.
Research and development expenses for the three months ended March 31,
1998 increased approximately $1,239,000 or 226% over the same period in 1997.
Current period increases were due primarily to costs and expenses associated
with the conduct of clinical trials, rent of the Company's new facility,
personnel additions, salary increases, consulting fees, research grants made by
the Company, and depreciation. In the same period in 1997, the Company had not
yet occupied its new facility and was conducting most of its research at offsite
facilities with fewer personnel and had begun its first clinical trial late in
the period. The Company expects its research and development expenses to
continue to increase as it expands its laboratories in its new facility and
increases its product development and clinical trial activities.
General and administrative expenses increased approximately $241,300 or
48% from the same period in 1997 due to facilities rent, the addition of
personnel, salary increases, insurance, professional and consulting fees, and
travel. The Company expects general and administrative expenses to increase in
future periods in support of the expected increases in research and development
activities as well as sales and marketing activities should the Company
successfully bring one or more of its products to market. Net interest income
decreased by approximately $200,000 due to the reduction of invested funds
remaining from the Company's public offering in September, 1996 and increased
interest expense on borrowings. The Company expects its interest earnings to
continue to decrease over the next year due to the use of its funds in current
operations.
13
<PAGE> 14
LIQUIDITY AND CAPITAL RESOURCES
- -------------------------------
From inception through March 31, 1998, the Company financed its
operations primarily through grants, sales of equity securities, borrowings and
deferred payment of salaries and other expenses from related parties. During
September and October 1996, the Company effected the public sale of a total of
2,700,000 units of its common stock and attached warrants to the public. Each
unit consisted of one share of common stock and one warrant to purchase one
share of common stock. The aggregate net proceeds of this offering amounted to
approximately $18,176,000
At March 31, 1998, working capital amounted to approximately $4.7
million. This amount included cash and cash equivalents of approximately $3.7
million and marketable securities and short-term investments of approximately
$2.2 million. In comparison, at December 31, 1997, the Company had working
capital of approximately $7 million, which included cash and cash equivalents of
approximately $7 million (of which approximately $0.9 million was restricted)
and marketable securities and short-term investments of approximately $2.1
million. The $2.3 million decrease in working capital during the three months is
attributable primarily to the operating loss for the period.
The Company is in the development stage devoting substantially all of
its efforts to research and development. During its development stage, the
Company has incurred cumulative losses of approximately $14.7 million through
March 31, 1998, and expects to incur substantial losses over the next several
years. In addition to the funds derived from its public offering, the Company
will require substantial additional funds in order to complete the research and
development activities currently contemplated and to commercialize its proposed
products. The Company's future capital requirements and availability of capital
will depend upon many factors, including continued scientific progress in
research and development programs, the scope and results of preclinical studies
and clinical trials, the time and costs involved in obtaining regulatory
approvals, the cost involved in filing, prosecuting and enforcing patent claims,
competing technological developments, the cost of manufacturing scale-up, the
cost of commercialization activities and other factors which may not be within
the Company's control. While the Company believes that its existing capital
resources will be adequate to fund its capital needs for at least 12 months, the
Company also believes that ultimately it will require substantial additional
funds in order to complete the research and development activities currently
contemplated and to commercialize its proposed products.
Without additional funding, the Company may be required to delay, reduce
the scope or eliminate one or more of its research and development projects, or
obtain funds through arrangements with collaborative partners or others which
may require the Company to relinquish rights to certain technologies, product
candidates or products that the Company would otherwise seek to develop or
commercialize on its own.
FACTORS AFFECTING FUTURE OPERATING RESULTS
- ------------------------------------------
The future operating results of the Company are highly uncertain, and
the following factors should be carefully reviewed in addition to the other
information contained in this quarterly report on Form 10-QSB:
The Company has incurred losses in every year of its existence and
expects to continue to incur significant operating losses for the next several
years. The Company has never generated revenues from product sales and there is
no assurance that revenue from product sales will ever be achieved. In
14
<PAGE> 15
addition, there is no assurance that any of the Company's proprietary products
will ever be successfully developed, receive and maintain required governmental
regulatory approvals, become commercially viable or achieve market acceptance.
The Company has no experience in manufacturing, procuring products in
commercial quantities or marketing, and only limited experience in negotiating,
setting up or maintaining strategic relationships and conducting clinical trials
or other late stage phases of the regulatory approval process, and there is no
assurance that the Company will successfully engage in any of these activities.
The Company's need for additional funding is expected to be substantial
and will be determined by the progress and cost of the development and
commercialization of its products and other activities. The Company believes
that its existing capital resources will be sufficient to satisfy its current
and projected funding requirements for at least the next twelve months. However,
if the Company experiences unanticipated cash requirements during the interim
period or fails to obtain sufficient funding under its recent $15 million line
of equity agreement, the Company could require additional funds sooner. The
source, availability, and terms of such funds have not been determined. Although
funds may be received from the sale of equity securities or the exercise of
outstanding warrants and options to acquire common stock of the Company, there
is no assurance any such funding will occur.
Factors impacting the future success of the Company include, among other
things, the ability to develop products which will be safe and effective in
treating neurological diseases and the ability to obtain government approval.
The Company faces numerous other risks in the operation of its business,
including, but not limited to, protecting its proprietary technology and trade
secrets and not infringing those of others; attaining a competitive advantage;
entering into agreements with others to source, manufacture, market and sell its
products; attracting and retaining key personnel in research and development,
manufacturing, marketing, sales and other operational areas; managing growth, if
any; and avoiding potential claims by others in such areas as product liability
and environmental matters.
The above factors are not intended to be inclusive. A more comprehensive
list of factors which could affect the Company's future operating results can be
found in the Company's Annual Report on Form 10-KSB for the fiscal year ended
December 31, 1997, in "Item 1. Description of Business" under the caption
"Factors Which May Affect Future Performance." Failure to satisfactorily achieve
any of the Company's objectives or avoid any of the above or other risks would
likely have a material adverse effect on the Company's business and results of
operations.
15
<PAGE> 16
PART II
OTHER INFORMATION
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
RECENT SALES OF UNREGISTERED SECURITIES
On March 27, 1998, the Company entered into a Private Equity Line of
Credit Agreement (the "Agreement") with a private investor, pursuant to which
the Company may issue and sell, from time to time, shares of its Common Stock
for cash consideration up to an aggregate of $15 million. Pursuant to the
requirements of the Agreement, the Company has filed a Registration Statement on
Form S-3 (the "Registration Statement") under the Securities Act of 1933 in
order to permit the investor to resell to the public any shares that it acquires
pursuant to the Agreement. Commencing as of the date the Registration Statement
is declared effective by the Securities and Exchange Commission and continuing
for a period of 30 months thereafter, the Company may from time to time at its
sole discretion, and subject to certain restrictions set forth in the Agreement,
sell ("put") shares of its Common Stock to the investor at a price equal to 88
percent of the then current average market price of the Company's Common Stock,
as determined under the Agreement. Puts can be made every 15 days in amounts
ranging from a minimum of $250,000 to a maximum of $2,000,000, depending on the
trading volume and the market price of the Common Stock at the time of each put.
The Company is required to put at least $1,000,000 of its Common Stock to the
investor over the life of the Agreement. To date, no shares of Common Stock have
been issued under the Agreement.
In conjunction with the Agreement, on March 27, 1998, the Company
issued to the investor a warrant (the "Warrant") which entitles the holder to
purchase 25,000 shares of Common Stock of the Company at a price of $11.61875
per share. The Warrant is exercisable at any time beginning on September 24,
1998 and ending on September 24, 2001. The Warrant contains provisions that
protect against dilution by adjustment of the exercise price and the number of
shares issuable thereunder upon the occurrence of certain events, such as a
merger, stock split or reverse stock split, stock dividend or recapitalization.
The exercise price of the Warrant is payable either (i) in cash or (ii) by a
"cashless exercise", in which that number of shares of Common Stock underlying
the Warrant having a fair market value at the time of exercise equal to the
aggregate exercise price are cancelled as payment of the exercise price.
Trinity Capital Advisors, Inc. ("Trinity") acted as a finder with
respect to the negotiation and execution of the Agreement. The Company has
issued 5,000 shares of its Common Stock to Trinity as consideration for the
services provided by Trinity in connection with the Agreement. In addition, the
Company is required to pay sales commissions to Trinity at the time of each put
pursuant to the Agreement in an amount equal to 5% of the amount of the purchase
price received by the Company in connection with each put. The commission is
payable to Trinity in cash and shares of the Company's Common Stock.
The securities issued and to be issued by the Company pursuant to
the transactions described above have been and will be issued without
registration under the Securities Act of 1933 in reliance upon the exemptions
from registration provided under Section 4(2) of the Securities Act and Rule 506
of Regulation D promulgated thereunder. The foregoing transactions did not
involve any public offering, the investors either received or had access to
adequate information about the Company in order to make
16
<PAGE> 17
an informed investment decision, and the Company reasonably believed that each
of the investors was "sophisticated" within the meaning of Section 4(2) of the
Securities Act.
USE OF PROCEEDS FROM REGISTERED SECURITIES
The following information is provided pursuant to Rule 463 of the
Securities Act and Item 701(f) of Regulation S-B in connection with the
Company's Registration Statement on Form SB-2 filed under the Securities Act:
<TABLE>
<S> <C>
(1) Effective date of Registration Statement: September 26, 1996
Commission file number: 333-05342-LA
(2) Date offering commenced: September 26, 1996
(3) Offering terminated before securities sold: Not applicable
(4) Disclosures:
(i) Has offering terminated: No
(ii) Managing underwriter(s): Paulson Investment Company, Inc.
First Colonial Securities Group, Inc.
(iii) Title of each class of securities registered: Common stock
Common stock purchase Warrants*
</TABLE>
*Each common stock purchase warrant entitles the holder to purchase one
share of common stock at an exercise price of $11.40 per share. The
common stock purchase warrants expire 5 years from September 26, 1996.
Outstanding common stock purchase warrants may be redeemed by the
Company, in whole or in part, at any time upon at least 30 days prior
written notice to the registered holders thereof, at a price of $0.25
per warrant, provided that the closing bid price of the common stock has
been at least $22.80 for the 20 consecutive trading days immediately
preceding the date of the notice of redemption.
(iv) Information regarding each class of securities:
<TABLE>
<CAPTION>
Common Stock
Common Purchase
Stock Warrants
----------- -----------
<S> <C> <C>
Amount registered 2,875,000 2,875,000
Aggregate offering price of
amount registered $21,850,000 $ 0
Amount sold 2,700,000 2,700,000
Aggregate offering price of
amount sold $20,520,000 $ 0
</TABLE>
17
<PAGE> 18
<TABLE>
<CAPTION>
(v) Expenses of offering: A* B*
---------- ----------
<S> <C> <C>
Underwriting discounts
and commissions $ 0 $ 1,436,400
Finders fees $ 0 $ 50,000
Expenses paid to or for underwriter $ 0 $ 331,317
Other expenses $ 0 $ 525,502
-----------
Total expenses $ 2,343,219
===========
(vi) Net offering proceeds $18,176,781
===========
(vii) Use of Net Proceeds through March 31, 1998:
</TABLE>
<TABLE>
<CAPTION>
A* B*
---------- -----------
<S> <C> <C>
Construction of plant, building and facilities $ 1,776,391
Purchase and installation of machinery and
equipment $ 1,950,858
Repayment of indebtedness $ 533,613 9,000
Working capital $ 8,122,180
TEMPORARY INVESTMENT
Money market and short-term investments $ 5,784,739
</TABLE>
*A: Direct or indirect payments to directors,
officers, general partners of the issuer
or their associates; to persons owning ten
percent or more of any class of equity
securities of the issuer; and to
affiliates of the issuer.
*B: Direct or indirect payments to others.
18
<PAGE> 19
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
4.1 Private Equity Line of Credit Agreement between
Registrant and Kingsbridge Capital Limited dated as of
March 27, 1998. (Filed as Exhibit 4.1 to the Company's
Registration Statement on Form S-3 (No. 333-52331), and
incorporated herein by reference.)
4.2 Registration Rights Agreement between Registrant and
Kingsbridge Capital Limited dated as of March 27, 1998.
(Filed as Exhibit 4.2 to the Company's Registration
Statement on Form S-3 (No. 333-52331), and incorporated
herein by reference.)
4.3 Warrant to Purchase up to 25,000 shares of Common Stock
of Registrant, issued to Kingsbridge Capital Limited as
of March 27, 1998. (Filed as Exhibit 4.3 to the
Company's Registration Statement on Form S-3 (No.
333-52331), and incorporated herein by reference.)
27. Financial Data Schedule
(b) Reports on Form 8-K
None
19
<PAGE> 20
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
NEOTHERAPEUTICS, INC.
Date: May 15, 1998 By: /s/ Alvin J. Glasky
---------------------------------
Alvin J. Glasky, Ph.D.,
President
Date: May 15, 1998 By: /s/ Samuel Gulko
---------------------------------
Samuel Gulko,
Chief Financial Officer
(Principal Acounting and
Financial Officer)
17
<PAGE> 21
EXHIBIT INDEX
Exhibit
Number Description
- ------ -----------
4.1 Private Equity Line of Credit Agreement between Registrant and
Kingsbridge Capital Limited dated as of March 27, 1998. (Filed as
Exhibit 4.1 to the Company's Registration Statement on Form S-3
(No. 333-52331), and incorporated herein by reference.)
4.2 Registration Rights Agreement between Registrant and Kingsbridge
Capital Limited dated as of March 27, 1998. (Filed as Exhibit 4.2
to the Company's Registration Statement on Form S-3 (No.
333-52331), and incorporated herein by reference.)
4.3 Warrant to Purchase up to 25,000 shares of Common Stock of
Registrant, issued to Kingsbridge Capital Limited as of March 27,
1998. (Filed as Exhibit 4.3 to the Company's Registration Statement
on Form S-3 (No. 333-52331), and incorporated herein by reference.)
27 Financial Data Schedule
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1998
<PERIOD-END> MAR-31-1998
<CASH> 3,669,957
<SECURITIES> 2,192,366
<RECEIVABLES> 91,351
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 6,195,356
<PP&E> 3,816,996
<DEPRECIATION> 386,648
<TOTAL-ASSETS> 9,840,443
<CURRENT-LIABILITIES> 1,451,098
<BONDS> 151,584
0
0
<COMMON> 23,378,034
<OTHER-SE> (15,151,849)
<TOTAL-LIABILITY-AND-EQUITY> 9,840,443
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 2,528,251
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 28,771
<INCOME-PRETAX> (2,508,291)
<INCOME-TAX> (2,508,291)
<INCOME-CONTINUING> (2,508,291)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (2,508,291)
<EPS-PRIMARY> (0.46)
<EPS-DILUTED> (0.46)
</TABLE>
